FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Preferred Pharmaceuticals Clindamycin Hydrochloride Capsules Recall

Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glen…

Preferred Pharmaceuticals, Inc. · Anaheim, CA

Risk level
Class II
Reported by FDA
May 7, 2025
Recall ID
D-0391-2025
Check your lot numberHow we source this data

Summary

Preferred Pharmaceuticals recalled Clindamycin Hydrochloride Capsules starting Apr 18, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0391-2025 on May 7, 2025. Reason: cGMP Deviations. Status: Ongoing.

Why it was recalled

cGMP Deviations

Product description

Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, NDC 68788-8685-03.

Lot numbers, UPCs & expiration codes

Lot #: L0224T, K1824M, K0124N, J1624V, J0824O, I2424E, I1024O, A0925F, L2324L, Exp: 7/31/2026.

Where it was sold

Nationwide in the US

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0391-2025
Classification
Class II
Status
Ongoing
Recall initiated
Apr 18, 2025
FDA report date
May 7, 2025
Quantity
1190 Bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Preferred Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-0391-2025, exactly as published.

Show all FDA fields
City
Anaheim
State
CA
Status
Ongoing
Country
United States
Event ID
96756
Address
1250 N Lakeview Ave Ste O
Code information
Lot #: L0224T, K1824M, K0124N, J1624V, J0824O, I2424E, I1024O, A0925F, L2324L, Exp: 7/31/2026.
Postal code
92807-1801
Report date
May 7, 2025
Product type
Drugs
Recall number
D-0391-2025
Classification
Class II
Recalling firm
Preferred Pharmaceuticals, Inc.
Product quantity
1190 Bottles
Reason for recall
cGMP Deviations
Voluntary / mandated
Voluntary: Firm initiated
Product description
Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, NDC 68788-8685-03.
Distribution pattern
Nationwide in the US
Recall initiation date
Apr 18, 2025
Initial firm notification
Letter
Center classification date
Apr 28, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0391-2025, published May 7, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls